BioLineRx reports additional Phase IIa data for BL-8040 in AML

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the expansion portion of a Phase IIa trial in 16 patients with

Read the full 205 word article

User Sign In